semaglutide
In April 2026 the FDA placed 12 compounding pharmacies on its 503B exclusion list, effectively cutting off bulk semaglutide purchases through the intermediary pathway. This means startups must either secure FDA-approved bulk supplies or build fully compliant in-house manufacturing to stay on the market. Medical Disclaimer: This article is for
semaglutide
Tirzepatide reduces major cardiac events by about 20% compared with semaglutide’s 12% reduction, making it the preferred option for patients focused on heart health. This advantage, combined with greater weight loss, drives many clinicians to favor tirzepatide for high-risk individuals. Medical Disclaimer: This article is for informational purposes only
semaglutide
Replacing semaglutide with tirzepatide can improve cardiovascular outcomes while preserving strong weight-loss effects, but the decision depends on individual risk factors and tolerability. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. Heart-worm question:
semaglutide
The new 7.2mg Wegovy pen reduces monthly drug spend by about 40%, saving roughly $40 per patient. This single-dose format streamlines pharmacy visits and keeps efficacy on par with the older multi-dose regimen. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always
semaglutide
The FDA’s draft rule could slash semaglutide supply by as much as 30% by removing it from the 503B bulk list. This change forces independent compounding pharmacies to either become full-scale manufacturers or risk losing access to a cornerstone GLP-1 therapy. Medical Disclaimer: This article is for informational purposes
semaglutide
Semaglutide can reduce the number of heavy-drinking days by about 35% in people with alcohol use disorder, according to a 2025 double-blind trial. The result points to a potential shift in how clinicians address cravings alongside weight management. In 2025, a pivotal double-blind study found that a GLP-1 agonist traditionally
semaglutide
Semaglutide reduces alcohol use disorder relapse rates by about 7 percent, offering a modest but measurable benefit for patients seeking sobriety support. Clinical trials show the drug also lowers cravings and improves metabolic health, making it a dual-action therapy for many adults. Did you know that semaglutide costs on average
semaglutide
Prescription weight-loss drugs like tirzepatide can dramatically lower mortality and improve heart health when used after bariatric surgery. In my practice, I see patients who think surgery alone solves everything, but the data tell a different story. Medical Disclaimer: This article is for informational purposes only and does not constitute
semaglutide
Semaglutide reduces overall healthcare costs for patients with alcohol use disorder by lowering hospital readmissions and outpatient visits. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. Semaglutide Cost-Benefit Analysis for Alcohol Use Disorder
semaglutide
GLP-1 therapy can cut heavy-drinking days by 52% and help patients lose weight, offering a dual solution for obesity and alcohol use disorder. In a recent pilot study, participants receiving a GLP-1 agonist saw heavy-drinking days drop by more than half within 12 weeks, while also shedding an average of
semaglutide
Answer: Semaglutide and tirzepatide do produce clinically meaningful weight loss, but they also bring muscle loss, costly side-effects, and an evolving market that may curb the current hype. In 2023, more than 100,000 new GLP-1 prescriptions were written in the United States, according to GoodRx, signaling a rapid shift
semaglutide
7 Surprising Ways Obesity Treatment Slashes Alcohol GLP-1 therapy for obesity reduces heavy drinking days and promotes weight loss, offering a dual benefit for patients who struggle with both conditions. Only 35% of heavy drinkers with obesity receive GLP-1 therapy - yet the latest trial shows it cuts heavy drinking